Janus Henderson Group PLC Rhythm Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 593,642 shares of RYTM stock, worth $40 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

593,642

Previous 621,427 4.47%

Holding current value

$40 Million

Previous $26.9 Million 9.48%

% of portfolio

0.01%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$35.41 - $44.37 $983,866 - $1.23 Million	-27,785 Reduced 4.47%	593,642 $24.4 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $18,190 - $24,384	-465 Reduced 0.07%	621,427 $26.9 Million
Q4 2023 Feb 14, 2024	SELL	$21.39 - $49.64 $9.49 Million - $22 Million	-443,853 Reduced 41.65%	621,892 $28.6 Million
Q3 2023 Nov 14, 2023	SELL	$15.81 - $27.8 $197,024 - $346,443	-12,462 Reduced 1.16%	1,065,745 $24.4 Million
Q2 2023 Aug 14, 2023	SELL	$16.32 - $21.15 $316,053 - $409,590	-19,366 Reduced 1.76%	1,078,207 $17.8 Million
Q1 2023 May 15, 2023	SELL	$16.88 - $34.24 $2.41 Million - $4.88 Million	-142,580 Reduced 11.5%	1,097,573 $19.6 Million
Q4 2022 Feb 14, 2023	SELL	$22.21 - $30.25 $7.13 Million - $9.71 Million	-320,930 Reduced 20.56%	1,240,153 $36.1 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $2.23 Million - $16 Million	-518,994 Reduced 24.95%	1,561,083 $38.2 Million
Q2 2022 Aug 15, 2022	SELL	$3.12 - $12.25 $2.72 Million - $10.7 Million	-870,925 Reduced 29.51%	2,080,077 $8.63 Million
Q1 2022 May 16, 2022	SELL	$6.13 - $12.24 $1.12 Million - $2.24 Million	-182,933 Reduced 5.84%	2,951,002 $34 Million
Q4 2021 Feb 14, 2022	SELL	$8.62 - $13.9 $417,613 - $673,413	-48,447 Reduced 1.52%	3,133,935 $31.3 Million
Q3 2021 Nov 16, 2021	SELL	$11.68 - $20.72 $8.69 Million - $15.4 Million	-743,668 Reduced 18.94%	3,182,382 $41.6 Million
Q2 2021 Aug 16, 2021	SELL	$18.52 - $22.55 $3 Million - $3.65 Million	-161,973 Reduced 3.96%	3,926,050 $76.9 Million
Q1 2021 May 17, 2021	SELL	$20.25 - $39.49 $8.18 Million - $15.9 Million	-403,742 Reduced 8.99%	4,088,023 $87 Million
Q4 2020 Feb 16, 2021	BUY	$21.17 - $32.61 $2.23 Million - $3.44 Million	105,395 Added 2.4%	4,491,765 $134 Million
Q3 2020 Nov 16, 2020	SELL	$18.13 - $30.61 $437,259 - $738,251	-24,118 Reduced 0.55%	4,386,370 $95.1 Million
Q2 2020 Aug 14, 2020	BUY	$14.41 - $25.35 $1.32 Million - $2.32 Million	91,455 Added 2.12%	4,410,488 $98.4 Million
Q1 2020 May 14, 2020	BUY	$13.16 - $22.9 $181,410 - $315,676	13,785 Added 0.32%	4,319,033 $65.7 Million
Q4 2019 Feb 18, 2020	BUY	$19.53 - $25.5 $17.5 Million - $22.9 Million	898,500 Added 26.37%	4,305,248 $98.8 Million
Q3 2019 Nov 14, 2019	BUY	$18.62 - $24.51 $2.13 Million - $2.8 Million	114,423 Added 3.48%	3,406,748 $73.6 Million
Q2 2019 Jul 31, 2019	BUY	$21.11 - $28.48 $222,837 - $300,634	10,556 Added 0.32%	3,292,325 $72.4 Million
Q1 2019 Apr 30, 2019	BUY	$24.76 - $31.66 $460,387 - $588,686	18,594 Added 0.57%	3,281,769 $90 Million
Q4 2018 Feb 06, 2019	BUY	$24.11 - $31.34 $5.12 Million - $6.65 Million	212,337 Added 6.96%	3,263,175 $87.7 Million
Q3 2018 Nov 09, 2018	BUY	$26.99 - $35.85 $20.5 Million - $27.2 Million	759,053 Added 33.12%	3,050,838 $89 Million
Q2 2018 Aug 10, 2018	BUY	$17.02 - $35.2 $20.4 Million - $42.1 Million	1,197,165 Added 109.37%	2,291,785 $71.6 Million
Q1 2018 May 14, 2018	BUY	$19.9 - $32.25 $6.76 Million - $10.9 Million	339,460 Added 44.95%	1,094,620 $21.8 Million
Q4 2017 Feb 09, 2018	BUY	$22.0 - $30.51 $16.6 Million - $23 Million	755,160	755,160 $21.9 Million

Others Institutions Holding RYTM

# of Institutions

180

Shares Held

68.5M

Call Options Held

467K

Put Options Held

224K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.75B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Rhythm Pharmaceuticals, Inc. Transaction History